News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Presidio Pharmaceuticals, Inc. Announces Clinical Proof-of-Concept Data for its First HCV NS5A Inhibitor, PPI-461, and Initiation of Clinical Testing for its Second-Generation NS5A Inhibitor, PPI-668


11/4/2011 6:40:08 AM

SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. today announced progress with its HCV antiviral drug discovery and development programs. A primary company objective is to advance multiple potent and safe inhibitors that target multiple HCV proteins and provide pan-genotypic coverage, as we believe such combination therapies will more adequately address the global medical need in the future. To that end, the company intends to bring 2 or 3 of its novel HCV NS5A inhibitors through early clinical development (Phase 1b/2a), with subsequent Phase 2-3 clinical evaluation of such NS5A candidates in suitable combination regimens with other HCV antivirals through corporate partnering or intercompany collaborations.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES